Indegene Share Price Today

Indegene concludes Digital Summit 2026 in Philadelphia

Indegene Digital Summit 2026 attracted 120+ senior life sciences leaders with 50% decision-maker representation. Speaker participation increased by 40% compared to the previous year, featuring 19 speakers. Key focus areas included operationalizing AI at scale and reimagining operating models for enterprise outcomes. Six industry leaders received Vital Awards for driving measurable impact in healthcare.

Indegene Q2 Results: board meeting scheduled for October 29

Indegene has scheduled a board meeting on October 29 to review Q2 financial results. No specific financial metrics or additional agenda details have been disclosed alongside the announcement.

Indegene hosts Digital Summit 2026 to drive AI outcomes in life sciences

Indegene Limited hosted the eighth Indegene Digital Summit in Philadelphia on September 22, 2026. Over 200 life sciences leaders attended to discuss operationalizing AI for enterprise outcomes. The VITAL Awards recognized leaders in Organizational Impact, Market Impact, and Transformational Leadership. Key themes included rewiring operating models to support precision medicines and AI-driven decision-making.

Indegene completes merger of German subsidiaries in internal restructure

Indegene merged indirect wholly owned subsidiaries Indegene Healthcare Germany GmbH and Trilogy Writing & Consulting GmbH on September 9, 2026. The transaction is an internal reorganization with no cash consideration or share exchange involved. Trilogy Writing & Consulting GmbH survives and changes its name to Indegene Healthcare Germany GmbH. The merger has no material impact on the listed entity's operations, shareholding, or financial position.

Indegene to host Premji Invest for analyst meeting on Sep 11

Indegene hosts Premji Invest for a one-on-one meeting. Session scheduled for September 11, 2026, in Bengaluru. Disclosure made under SEBI LODR Regulations 2015. No unpublished price-sensitive information to be shared.

Indegene gets US court preliminary approval for USD 4.72 million class action settlement

U.S. court preliminarily approves class action settlement for Indegene Inc. Maximum settlement fund capped at approximately USD 4.72 million. Eligible claimants to receive USD 250 per approved claim. Final approval hearing scheduled for January 12, 2027. Settlement follows a claims-made structure with no pre-funding required.